Information Library

Results for: Oncology - Enrollment & retention

To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.

Start Over

  • Sort by:
  • Recently Added
  • Title
  • Energizing Enrollment

    Case Study — October 4, 2011
    The rapid recruitment for this Phase III, open, randomized, controlled, multi-center study in adjuvant triple-negative breast cancer (TNBC) was completed two months earlier than planned.

  • Recruiting Trust

    Case Study — March 16, 2011
    Quintiles enrolls 2 cancer trials, 2 times faster than projected

  • Breakthrough Motivation

    Case Study — June 24, 2010
    Quintiles' Expertise, Network Maximize Recruitment

  • Strategic Communication

    Case Study — June 24, 2010
    Exceeding Global Recruitment Targets - 6 Months Early

  • Extraordinary Results

    Case Study — June 24, 2010
    9-Month Savings Nets 50% More Patients

  • Data-Driven Patient Recruitment

    White Paper — March 23, 2010
    Under pressure to deliver more evidence faster, drug developers are constantly searching for more patients for clinical trials.

  • Multinational Coordination

    Case Study — February 26, 2010
    Coordinating a non-Hodgkin’s lymphoma study across six countries, our expert team exceeded expectations for efficiency and communication.

  • Sub-Saharan Africa Phase II/III Fact Sheet

    Brochure — July 29, 2009
    Sub-Saharan Africa fact sheet about Phase II/III trials. The gateway to Africa: Access to expanded clinical resources and patient populations in South Africa and beyond.

  • QUINTILES ANNOUNCES NEW GHANA OFFICE

    Press Release — June 16, 2009 - To improve efficiency and expand capacity to monitor the growing number of clinical studies being conducted in Western Sub-Saharan Africa, Quintiles announced the opening of a new office in Accra, Ghana.

  • Contracting Timeline

    Case Study — March 27, 2009
    Aggressive Recruitment Speeds Time to Market. The goal: to accelerate a study of a top-priority drug for non-myeloid malignancy. Quintiles ramped up 36 sites in just two months.

Page 1 of 2 (11 results)

Subscribe to Email Based on Your Interests

Set preferences